CD79A and neoplasm: The comprehensive assessment of tumor response includes clinical examination, nasendoscopy with or without biopsy, Epstein–Barr virus (EBV) DNA or virus capsid antigen-specific IgA (VCA-IgA) titer measurement, and radiological imaging [4].